H. Bakhouche

Impact of ABCB 1 and CYP 2 D 6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients

O. Slanař, S. Argalácsová, H. Bakhouche, 2017 .

Therapeutic drug monitoring of antibiotic agents: evaluation of predictive performance

O. Slanař, M. Šíma, J. Hartinger, 2017, European journal of hospital pharmacy. Science and practice.

Contribution of ABCB 1 and CYP 2 D 6 Genotypes to the Outcome of Tamoxifen Adjuvant Treatment in Premenopausal Women With Breast Cancer

O. Slanař, T. Zima, P. Vítek, 2015 .

Contribution of ABCB1 and CYP2D6 genotypes to the outcome of tamoxifen adjuvant treatment in premenopausal women with breast cancer.

O. Slanař, T. Zima, P. Vítek, 2015, Physiological research.

Drug-induced photosensitivity

O. Slanař, M. Šíma, H. Bakhouche, 2017 .

[Magistral prepared lidocaine-gel for topical aplication on skin].

O. Slanař, Z. Sklenář, H. Bakhouche, 2012, Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti.

Pharmacogenetics of Chronic Pain and Its Treatment

O. Matoušková, O. Slanař, K. Hronová, 2013, Mediators of inflammation.

Maternal and Neonatal Effects of Remifentanil in Women Undergoing Cesarean Section in Relation to ABCB 1 and OPRM 1 Polymorphisms

O. Slanař, J. Ulrichová, A. Pařízek, 2015 .

Neonatal effect of remifentanil in general anaesthesia for caesarean section: a randomized trial

O. Slanař, J. Ulrichová, A. Pařízek, 2015, BMC Anesthesiology.

Maternal and neonatal effects of remifentanil in women undergoing cesarean section in relation to ABCB1 and OPRM1 polymorphisms.

O. Slanař, J. Ulrichová, A. Pařízek, 2015, Physiological research.

Pharmacogenetics in clinical practice.

O. Slanař, H. Bakhouche, 2012, Prague medical report.

Impact of ABCB1 and CYP2D6 polymorphisms on tamoxifen treatment outcomes and adverse events in breast cancer patients.

O. Slanař, S. Argalácsová, H. Bakhouche, 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.